
The American Journal of #ManagedCare is a peer-reviewed, indexed publication. https://nitter.cf/t.co/I2WRhmhOVC offers news in health policy, disease states, and managed care.
Cranbury, NJ
Joined July 2009
- Tweets45.5K
- Following888
- Followers7.1K
- Likes2.4K
In a recent interview with #AJMC, Mike Sharma, MD, discussed early efficacy signals, long-term #stroke risk, patient impact, and why antithrombotic treatment should be tailored to each condition.
Watch here: hubs.li/Q04FmPMj0
40
Research at #ObesityWeek 2026 tracks rising obesity in #Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
Learn more here: hubs.li/Q04FmNxb0
58
In this recap video, experts at The Liver Meeting 2026 (#TLM26), run by @AASLDtweets, share the research they expect will most shape #liver care, from new biomarkers to emerging #MASH drugs.
Watch here: hubs.ly/Q04FfkfW0
Earlier diagnosis can make a meaningful difference, but how can clinicians show its value to #payers?
Experts discuss the case for earlier Lambert-Eaton myasthenic syndrome screening in small cell lung cancer 👇
hubs.li/Q04Dkf6R0
#LEMS #SCLC #LungCancer
92
Fit for chemotherapy, but is it the right choice?
Experts examine psychosocial burdens, quality of life, and treatment decisions for older patients with acute myeloid leukemia (AML).
Watch: hubs.li/Q04DmWt00
#AML #Oncology #PatientCare
60
Six studies presented at @AASLDtweets The Liver Meeting 2026 (#TLM26) found #liver transplant disparities by insurance, region, ethnicity, and sex, plus links between unmet social needs and frailty in #cirrhosis.
Learn more here: hubs.li/Q04F2ynT0
A new tool puts this year's #measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Learn more here: hubs.li/Q04F2wPD0
58
#SGLT2 inhibitors protect the heart and kidneys, not just glucose.
So why are 𝐞𝐥𝐢𝐠𝐢𝐛𝐥𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐬𝐭𝐢𝐥𝐥 𝐦𝐢𝐬𝐬𝐢𝐧𝐠 𝐨𝐮𝐭?
Watch this video on fragmented care, specialty silos, and how payers can close the gap: hubs.li/Q04CcpfG0
#CKD #ManagedCare
56
Experts told #AJMC at the GOLD International COPD Conference that earlier diagnosis and intervention could most improve #COPD outcomes within 5 years.
Watch here: hubs.li/Q04DM3Tz0
50
#Diabetes and functional dependence, not severe #obesity alone, were linked to higher graft failure 3 years after liver transplant for #MASH, according to Sri Harsha Boppana, MD, at AASLD’s The Liver Meeting 2026 (#TLM26).
Watch here: hubs.li/Q04DM2YW0
#HepatitisB functional cure with #bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026 (#TLM26).
Learn more here: hubs.li/Q04DM29z0
Building a cellular therapy program is one challenge. Delivering treatment across the full patient journey is another.
Register today: hubs.li/Q04CNt9Y0
Looking forward to hearing insights from Ahmed Galal, Tracy Schoenhoft, Jehad Al Masri, and Christine Pfaff!
64
Guidelines have urged #AATD testing for every #COPD patient since 1989, yet testing is still rare. Experts discuss who gets missed, the 5- to 8-year diagnostic delay, and what health plans can do.
Learn More: hubs.li/Q04Cn6cB0
58
In part 2 of an interview at #AMCPNexus 2026, Leanna Baker, PharmD, MS, of @CencoraGlobal discussed the ongoing costs, governance, and oversight needed for responsible #AI adoption.
Watch here: hubs.li/Q04DlMbT0
75
At @amcporg Nexus 2026, experts discussed how drug pricing policy, AI, and high-cost cell and gene therapies may shape managed care in 2027.
Watch the conference recap video here: hubs.li/Q04DlJr30
#AMCPNexus #AI #policy #managedcare
1
66
As cellular therapy moves into community oncology, are traditional reimbursement models keeping pace?
Join the discussion to hear more from physicians and advanced practice providers.
👉 Register for the free webinar: hubs.li/Q04CNncj0
67
When standard #MAC therapy fails, options are few.
Learn more about a phase 2/3 trial of an all-oral bedaquiline regimen for refractory Mycobacterium avium complex #LungDisease and why #QTc monitoring still matters.
𝐖𝐚𝐭𝐜𝐡: hubs.li/Q04zFHRJ0
79
Delivering cellular therapy requires expertise and coordination across the entire patient journey.
Gain insights from physicians and advanced practice providers.
💻 Free webinar on Monday, November 9, at 4 p.m. EST
👉 Register now: hubs.li/Q04CNbZF0
69
A serum AAT level is a snapshot. #Genotype is the blueprint. Experts explain why levels alone can miss #AATD carriers, and why fewer than 10% of people with severe AATD may be diagnosed.
𝐖𝐚𝐭𝐜𝐡 𝐭𝐡𝐞 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧: hubs.li/Q04C2znr0
1
62
In the first phase 3 head-to-head trial pitting #retatrutide against another incretin, Eli Lilly’s triple agonist beat the highest approved diabetes dose of #semaglutide on both glucose control and weight.
Read more: hubs.li/Q04CCZfb0
114

















